Compare AbbVie Inc (ABBV) vs VanEck Australian Floating Rate ETF (FLOT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs VanEck Australian Floating Rate ETF — how do they compare? AbbVie Inc trades at $253.58 (market cap $449.91B), while VanEck Australian Floating Rate ETF trades at $50.97. The key difference: AbbVie Inc pays a 2.72% dividend while VanEck Australian Floating Rate ETF pays none, and AbbVie Inc is trading nearer its 52-week high, VanEck Australian Floating Rate ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | FLOT | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Sector/Thematic |
52-Week High | $261.07 | $51.09 |
52-Week Low | $184.85 | $50.72 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
FLOT trades at $50.96, up 0.08% on the day, with a bearish technical signal from moving averages and oscillators showing neutral momentum. The ETF focuses on high-quality floating rate bonds, offering a 4.0% SEC yield, and recent dividends include $0.18 paid in June 2026. News highlights potential Fed rate hikes as a catalyst for yield growth, while credit quality remains strong with minimal default risk.
Outlook is cautious due to bearish technicals and interest rate uncertainty, but FLOT provides a stable income stream with low credit risk. Key risks include inflation-driven rate volatility and economic shifts affecting bond yields, making it suitable for investors seeking short-term cash parking with modest returns above Treasuries.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →
